Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Caremark To Join Medco In Applying To Be National Medicare Rx Sponsor

This article was originally published in The Pink Sheet Daily

Executive Summary

Assuming both PBMs are approved as national Part D sponsors, there will be no need for “fallback” plans in 2006. Caremark, like Medco, is stressing a desire to sell Part D through health plan and employer clients.

You may also be interested in...



CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says

Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.

CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says

Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.

Caremark May Offer "Open" Medicare Rx Plan In Some Regions

The pharmacy benefit manager is deciding whether to offer standalone drug plans in regions in which it does not have employer or health plan partners, CEO Crawford says. The exec notes some of Caremark's clients will "aggressively" market their plans to individuals for 2006.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel